Zobrazeno 1 - 10
of 41
pro vyhledávání: '"Pei-Shi Ong"'
Autor:
Shermain Yali Ng, Nunzio Cardullo, Samuel Chao Ming Yeo, Carmela Spatafora, Corrado Tringali, Pei-Shi Ong, Hai-Shu Lin
Publikováno v:
Molecules, Vol 19, Iss 7, Pp 9577-9590 (2014)
trans-2,3-Dimethoxystilbene (2,3-DMS) and trans-3,4-dimethoxystilbene (3,4-DMS) are two synthetic resveratrol (trans-3,5,4'-trihydroxystilbene) analogs. In this study, a simple HPLC method was developed and validated to determine 2,3-DMS and 3,4-DMS
Externí odkaz:
https://doaj.org/article/e1423e5d09c244ee970f5213b688967f
Autor:
Janelle M Hoskins, Pei-Shi Ong, Temitope O Keku, Joseph A Galanko, Christopher F Martin, Clint A Coleman, Michelle Wolfe, Robert S Sandler, Howard L McLeod
Publikováno v:
PLoS ONE, Vol 7, Iss 7, p e41954 (2012)
Low-penetrance genetic variants have been increasingly recognized to influence the risk of tumor development. Risk variants for colorectal cancer (CRC) have been mapped to chromosome positions 8q23.3, 8q24, 9p24.1, 10p14, 11q23, 14q22.2, 15q13, 16q22
Externí odkaz:
https://doaj.org/article/303f47395a3c4e47ac2db81b70e48504
Autor:
Yu Heng Kwan, Livia Oh, Pui Kim Ang, Zhonghui Xiong, Pei Xin Chong, Chin Teck Ng, Sungwon Yoon, Pei Shi Ong, Silvana X. Choo, Ying Ying Leung, Julian Thumboo, Warren Fong
Publikováno v:
Journal of Clinical Rheumatology and Immunology, Vol 24, Iss supp01, Pp 19-19 (2024)
Objective: We aimed to provide an up-to-date synthesis of the effectiveness of patient reported outcome measures (PROMs) use to self-monitor symptoms compared to conventional follow-up care in patients with rheumatic diseases. We also compared the ef
Externí odkaz:
https://doaj.org/article/7dd0cfaa9016444598623785a6ed2327
Autor:
Andrea Li Ann Wong, Arul Goel, Gautam Sethi, Lingzhi Wang, Xiaoqiang Xiang, Paul C. Ho, Pei Shi Ong, Ling-Wen Ding, Boon Cher Goh, Hannah Ying Lim
Publikováno v:
Cancer Letters. 521:252-267
Cancer is one of the world's biggest healthcare burdens and despite the current advancements made in treatment plans, the outcomes for oncology patients have yet to reach their full potential. Hence, there is a pressing need to develop novel anti-can
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e73be9a310c6fa2392e684ff7865d81
https://doi.org/10.1016/j.canlet.2021.08.030
https://doi.org/10.1016/j.canlet.2021.08.030
Autor:
Andrea Li-Ann Wong, Xiaoqiang Xiang, Pei Shi Ong, Ee Qin Ying Mitchell, Nicholas Syn, Ian Wee, Alan Prem Kumar, Wei Peng Yong, Gautam Sethi, Boon Cher Goh, Paul Chi-Lui Ho, Lingzhi Wang
Publikováno v:
Pharmaceutics, Vol 10, Iss 4, p 221 (2018)
In the last decade, the tremendous improvement in the sensitivity and also affordability of liquid chromatography-tandem mass spectrometry (LC-MS/MS) has revolutionized its application in pharmaceutical analysis, resulting in widespread employment of
Externí odkaz:
https://doaj.org/article/3d80f2441f544d779a760985c2e69c3a
Autor:
Boxu Ren, Zhaowu Ma, Ling-Wen Ding, Paul C. Ho, Xiaoqiang Xiang, Marabeth Xin-Yi Kwah, Lingzhi Wang, Muthu K. Shanmugam, Cuiliu Liu, Pei Shi Ong, Boon Cher Goh
Publikováno v:
Cancer letters. 515
Resveratrol (3,4',5-trihydroxy-trans-stilbene) has been expected to ameliorate cancer and foster breakthroughs in cancer therapy. Despite thousands of preclinical studies on the anticancer activity of resveratrol, little progress has been made in tra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc19e6011b36d7e8aa9390e6ef55405a
https://pubmed.ncbi.nlm.nih.gov/34052324
https://pubmed.ncbi.nlm.nih.gov/34052324
Autor:
B.G. Abdallah, M.M. Ali, Merwan Benhabib, Sui Yung Chan, E. Chang, L.T. Chau, J.J. Cooper–White, Sreekant Damodara, Dawei Ding, Xianke Dong, Ryan F. Donnelly, M.A. Eckert, H.O. Fatoyinbo, J. Friend, J.E. Frith, Wupeng Gan, Ning Gao, Farid Ghamsari, Samar Haroun, Yi He, Mei He, Marie Hébert, Huan-Hsuan Hsu, Sarah Innis, Siwat Jakaratanopas, Xingyu Jiang, D.-K. Kang, Lifeng Kang, Melissa Kirkby, Jaspreet Singh Kochhar, Jonathan Lee, Won Gu Lee, Paul C.H. Li, XiuJun (James) Li, Peng Liu, Xinyu Liu, J. Lu, Sharon Lu, Emma McAlister, Joshua E. Mendoza-Elias, D.J. Menzies, R.J. Mills, José Oberholzer, Pei Shi Ong, Peng Pan, Sol Park, Sui Ching Phung, Kimberly Plevniak, Melur K. Ramasubramanian, Carolyn L. Ren, Pouya Rezai, A. Rezk, A. Ros, Ravi Selvaganapathy, Shadi Shahriari, Pengfei Song, M. Sonker, Jiashu Sun, Yu Sun, D.M. Titmarsh, Yong Wang, Wen-I Wu, Yuan Xing, L. Yeo, Xiaoyu Yu, Pu Zhang, W. Zhang, Weize Zhang, W. Zhao, Wenfu Zheng, Yu Zhou, Qingfu Zhu, Bin Zhuang
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::686a87fa15a4b33b5a3c98ad91e0621f
https://doi.org/10.1016/b978-0-12-819971-8.01002-7
https://doi.org/10.1016/b978-0-12-819971-8.01002-7
Autor:
Won Gu Lee, Lifeng Kang, Dawei Ding, Jaspreet Singh Kochhar, Pei Shi Ong, Sui Yung Chan, Sol Park
Publikováno v:
Microfluidic Devices for Biomedical Applications ISBN: 9780128199718
Microdevices, since their inception in the last decade of 20th century, have changed our outlook toward science and technology due to their potential applications in fields ranging from optics, semiconductors, and microelectronics industry to drug di
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a4c3462cb60412d93e80cf70e0b72b74
https://doi.org/10.1016/b978-0-12-819971-8.00019-6
https://doi.org/10.1016/b978-0-12-819971-8.00019-6
Publikováno v:
Phase I Oncology Drug Development ISBN: 9783030476816
The ultimate goal of therapeutics is to ensure that the appropriate treatment is administered to the individual patient at the most appropriate dose for optimal effects. In drug development, clinical trials are conducted in 3 broad phases (Phase I, I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5e0efcb930f0ebf4d6e1a4909b1571a1
https://doi.org/10.1007/978-3-030-47682-3_8
https://doi.org/10.1007/978-3-030-47682-3_8
Publikováno v:
Journal of Pharmaceutical Health Services Research. 8:91-99
Objectives Prescribing drugs outside regulatory recommendation is known as off-label use. Studies have reported widespread off-label drug use in oncology practice. But the clinical, economic and humanistic outcomes for such practice are often uncerta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::17b29c3b5a979bfb3faac70c014989b5
https://doi.org/10.1111/jphs.12175
https://doi.org/10.1111/jphs.12175